Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:22:11 EDT Thu 12 Jun 2025
Enter Symbol
or Name
USA
CA



Q:LXRX - LEXICON PHARMACEUTICALS INC - https://www.lexpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LXRX - Q0.10.6776·0.769.50.7021    2.45  0.2836Jun 11May 2915 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-29 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
2025-05-19 08:00U:LXRXNews ReleaseSONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
2025-05-13 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
2025-05-06 16:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
2025-05-06 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
2025-04-02 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
2025-03-28 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
2025-03-07 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
2025-03-06 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
2025-03-04 16:15U:LXRXNews ReleaseLexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
2025-03-03 07:00U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
2025-03-02 16:13U:LXRXNews ReleaseLexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
2025-02-18 08:00U:LXRXNews ReleasePublished Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
2025-01-21 08:00U:LXRXNews ReleaseLexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
2025-01-02 08:00U:LXRXNews ReleaseLexicon Appoints Scott Coiante as Chief Financial Officer
2024-12-20 16:31U:LXRXNews ReleaseLexicon Announces Receipt of Complete Response Letter for Zynquista(TM) (sotagliflozin)
2024-11-26 08:00U:LXRXNews ReleaseLexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
2024-11-25 16:15U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in December Investor Conferences
2024-11-22 07:32U:LXRXNews ReleaseLexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
2024-11-20 16:06U:LXRXNews ReleaseLexicon Appoints Ivan H. Cheung to Board of Directors